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1. Introduction 
Maintenance of blood glucose homeostasis is fundamentally important for health. The 
maintain of stable levels of glucose in the blood is one of the most finely regulated of all 
homeostatic mechanisms and one in which the liver, the extrahepatic tissues, and several 
hormones play a part. Even mild disruptions of glucose homeostasis can have adverse 
consequences. 
The physiological post absorptive serum glucose concentration in healthy humans range 
is 4, 4-5,8 mmol/L (80 to 105 mg/dL). The stability of the plasma glucose level is a 
reflection of the balance between the rates of whole body glucose production and glucose 
utilization. 
Generally, hypoglycemia is defined as a serum glucose level below 3. 8 mmol/L (70 
mg/dL).As a relatively rare disorder, hypoglycemia most often affects those humans at the 
extremes of age, such as infants and the elderly, but may happen at any age. 
As a medical problem, hypoglycemia is diagnosed by the presence of three key features 
(known as Whipple's triad). Whipple's triad is:  
1. symptoms consistent with hypoglycemia,  
2. a low plasma glucose concentration, and  
3. relief of symptoms after the plasma glucose level is raised.  
The etiology of hypoglycemia is numerous:  
1. Inborn error of metabolism (more common in the pediatric patient than in adults). 
Disturbance in carbohydrates metabolism: Malabsorption of glucose/galactose, 
alactasia, asucrasia, galactosemia, fructose intolerance. Glycogen storage disease, Type I 
,or von Gierke Disease, glycogen storage disease, Type III, a deficiency of glycogen 
disbranching enzyme activity ( limit dextrinosis),  Type VI glycogen storage disease, a 
deficiency of liver phosphorylase ) 
2. Hormonal disturbance  .The hormone insulin plays a central role in the regulation of the 
blood glucose concentration. It is produced by the  cells of islets of Langerhance in the 
pancreas. Insulin exerts hypoglycemic effect. Glucagon is the hormone produced by the  
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cells of Langerhance islets in the pancreas. Its secretion is stimulated by hypoglycemia. 
The hormone glucagon, epinephrine, norepinephrine, growth hormone, and cortisol exert 
the opposite effects to insulin and they belong in the counter-regulatory hormones 
3. The disorders of some organs (Liver and Kidney Disorders especially). Any 
abnormality in the functioning of the liver can disturb the process of blood-sugar 
regulation, resulting in hypoglycemia. On the other hand, kidney disorder can be one of 
the major causes of low blood sugar. 
4. Infection-related hypoglycemia (in older adults) 
5. The adverse medication reactions  
6. Hypoglycemia as the complication of treatment of diabetes mellitus. 
The central nervous system requires glucose as its primary fuel. The brain uses more than 30% 
of blood glucose. The brain does not produce the glucose required for its functioning and it is 
completely dependent on the rest of the body for its supply. So, fluctuations in blood sugar 
levels can prove to be harmful for the brain; a continual supply of glucose is necessary as a 
source of energy for the nervous system and some other organs like erythrocytes, testes and 
kidney medulla .Gluconeogenesis, the biosynthesis of new glucose, (i.e. not glucose from 
glycogen) from other metabolites (lactic acid, amino acids and glycerol) is necessary for use as 
a fuel, since glucose is the sole energy source for these organs. 
The symptoms caused by low blood sugar come from two sources and may resemble other 
medical conditions. The first symptoms are caused by the release of epinephrine from the 
nervous system. These include sweating, pale skin color, shakiness, trembling, rapid heart 
rate, a feeling of anxiety, nervousness, weakness, hunger, nausea and vomiting. Lowering of 
the brain's glucose causes: headache, difficulty in thinking, changes in vision, lethargy, 
restlessness, inability to concentrate or pay attention, mental confusion, sleepiness, stupor, 
and personality changes.  
To treat low blood sugar immediately the patients should eat or drink something that has 
sugar in it, such as orange juice, milk, or a hard candy. It is need to find out the causes of 
hypoglycemia.  
Laboratory diagnosis of hypoglycemia is very important in medical praxis especially in 
pediatric, internal medicine (hepatology, renal failure, and cardiology) neuropsychiatry 
disorders and so on.   
Glucose is the name of the simple sugar found in plant and animal tissues. It is made within 
plants as a product of photosynthesis. Although glucose can be produced within the human 
body, most of it is supplied to people by dietary carbohydrate intake principally as starch. 
Once consumed and digested, glucose will either be used immediately or stored as glycogen 
for future use, (Caraway & Watts,1986; Mayer,1975). 
Glucose is the major energy source for human body and is derived primarily from dietary 
carbohydrates (grains, starchy vegetables, and legumes), from body stores of   
carbohydrates (glycogen) and from the synthesis of glucose from protein and glycerol 
moiety of triglycerides (gluconeogenesis) (King, 2011). 
The glucose level in blood is kept within narrow range through a variety  of influences. 
While there is some variation in blood glucose as circumstance changes (feeding, prolonged 
fasting), levels above or below the normal range usually indicate disease.  
High blood glucose due to diabetes mellitus is the most commonly encountered disorder of 
carbohydrate metabolism. Low blood glucose is an uncommon cause of serious diseases. 
There are numerous rare conditions that cause hypoglycemia in neonatal period and early 
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childhood. In adults, low blood glucose in the fasting state is almost  always due to a serious 
underlying condition (Caraway & Watts,1986; King, 2011; Mayer, 1975; Service,1992). 
2. Digestion and absorption of carbohydrates  
Carbohydrates are important components of the diet. The carbohydrates that we ingest 
range from simple monosaccharides (glucose, fructose and galactose) to disaccharides 
(lactose, sucrose) and complex polysaccharides, starch and glycogen. Most carbohydrates 
are digested by salivary and pancreatic amylases, and are further broken down into 
monosaccharides by enzymes in the brush border membrane (BBM) of enterocytes. Maltase, 
lactase and sucrase-isomaltase are disaccharidases involved in the hydrolysis of 
nutritionally important disaccharides, maltose, lactose,  saccharose. Once monosaccharides 
are presented to the BBM, mature enterocytes, expressing nutrient transporters, transport 
the sugars into the enterocytes, (Drozdowski & Thomson, 2006). 
The resultant glucose and other simple carbohydrates, galactose (from lactose) and fructose 
(from succrose) are transported across the intestinal wall to the hepatic portal vein and then 
to liver parenchymal cells. Both fructose and galactose are readily converted to glucose by 
hepatocytes Absorption of glucose and galactose occurs by an active carrier-mediated 
transfer process. Fructose is absorbed by facilitated diffusion (Harper,1975; King, 2011; 
www.deo.ucsf.edu/type1/understanding-diabetes). 
Fructose and galactose  are phosphorylated by specific enzymes, fructokinase and 
galactokinase, presented only in the liver, and converted to glucose. Glucose is transported 
from the liver via the bloodstream to be used by all the body cells as the most important 
source of energy. Glucose, as unique sugar in systemic blood circulation, leaves the blood, 
enters cells through specific transport proteins and has one principal fate: it is 
phosphorylated by ATP to form glucose-6-phosphate by hexokinase in all human body cells 
or  by the action of glucokinase in hepatocytes. This step is notable because glucose-6-
phosphate cannot diffuse through the membrane out of the cells (Haris, 1997; Harper,1979; 
King,2011; Tietz,1986; Voet & Voet, 2004a).  
3. Glycemia - Physiological regulation 
Maintenance of blood glucose homeostasis is fundamentally important for health. The 
plasma glucose level is tightly controlled throughout life in the normal individual, in spite 
of intermittent food ingestion and periods of fasting, as the net balance between the rates of 
glucose production and utilization. The stability of the plasma glucose level is a reflection of 
the balance between the rates of whole body glucose production and glucose utilization. 
The amount of plasma glucose level  in healthy humans  is usually maintained within a 
range of 4.4 to 5.8 mmol/L , 80 to 110 mg/dL), (Carraway & Watts,1986; King, 2011; 
Mayes,1975; Service, 1992; Voet & Voet, 2004a). 
4. Intermediary metabolism of carbohydrates 
4.1 Glycogen synthesis 
Glycogen is the storage form of glucose and serves as a tissue reserve for the body's glucose 
needs. Glycogen synthesis occurs in virtually all animal tissues, but it is especially 
prominent in the liver and skeletal muscles. In the liver, glycogen serves as a reservoir of 
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glucose, readily converted into blood glucose for distribution to other tissues, whereas in 
muscles glycogen is broken down via glycolysis to provide energy for muscle contraction. In 
human body, glycogen is synthesized and stored when glucose levels are high and is broken 
down during starvation or periods of high glucose demand.  
Glycogen is a highly branched polymeric structure containing glucose as the basic monomer 
(Mayes, 1975; Voet & Voet, 2004b). It is composed of polymers of  -1-4 linked glucose, 
interrupted by  1-6 linked branch point every 4-10 residues  (Fig 1). 
 
 
Fig. 1. Glycogen structure 
Uridine diphosphate glucose (UDP-glucose) is the immediate precursor for glycogen 
synthesis. Glycogen synthase will only add glucose units from UDP-glucose onto a 
preexisting glycogen chain that has at least four glucose residues. Linkage of the first few 
glucose units to form the minimal "primer" needed for glycogen synthase recognition is 
catalyzed by a protein called glycogenin, which attaches to the first glucose and catalyzes 
linkage of the first eight glucoses by alpha(1,4) bonds. The enzyme, glycogenin, initiates 
glycogenynthesis (oregonstate.edu/.../summer09/lecture/glycogennotes.html; Voet & 
Voet, 2004b). 
The enzyme glycogen synthase then catalyzes elongation of glycogen chains initiated by 
glycogenin to a chane of  9 – 11 glucose molecule. Glycogen synthase catalyzes transfer of 
the glucose moiety of UDP-glucose to the hydroxyl at C4 of the terminal residue of a 
glycogen chain to form an   (1-4)-glycosidic linkage (Fig 2) (Mayes,1975; King, 2011; Voet & 
Voet, 2004b; www.uic.edu/.../glycogen%20metab/Glycogen%20biochemistry.htm). 
A branching enzyme forms the branching points in glycogen.  The branches arise from -(1-
6) linkages which occur every 8 to 12 residues. Glycogen branches are formed by amylo-(1,4-
1,6)-transglycosylase, also known as branching enzyme. The branching enzyme transfers a 
segment from the end of a glycogen chain to the C6 hydroxyl of a glucose residue of 
glycogen to yield a branch with an -(1-6) linkage. In the presence of glycogenin, glycogen 
synthase, branching enzyme and UDP glucose (active glucose) form glycogen as a highly 
branched polymeric structure,  containing glucose as the basic monomer (Figure 2).  
Glycogen is synthesized and stored mainly in the liver and the muscles as well as in the 
cytoplasm of all human body cells as granules named ”residual bodies", (Voet & Voet, 2004b). 
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Fig. 2. Glycogenesis  
4.2 Glycogen breakdown (glycogenolysis)  
In the proceses of glycogen catabolism or glycogenolysis, glycogen, stored in the liver and 
muscles, is converted first to glucose-1-phosphate and then into glucose-6-phosphate. 
(Mayes,1975; Voet &;Voet, 2004b). Three enzymes participate in glycogenolysis: glycogen 
phosphorylase, oligo-1,4-1,4–glucan transferase or trisaccharide transferase, and (1-6) 
glucosidase or - amylase. Glycogen phosphorylase catalyzes phosphorolytic cleavage of the 
-1,4 glycosidic linkages of glycogen (using inorganic phosphate), releasing glucose-1-
phosphate as reaction product and limit dextrin. After extensive phosphorylase action on 
glycogen, the molecule contains four glucose residues in -1,4-glucosidic bond attached by 
a(1,6)-link to the glycogen molecule.  
These structures can be further degraded by the action of a debranching enzyme, which 
carries out two distinct reactions. The first of these, known as oligo-a1,4-a-1,4) glucan 
transferase activity or trisaccharide transferase, removes a trisaccharide unit from limit 
branch and transfers this group to the end of another nearby glycogen chain, with 
resynthesis of the -1,4 bond. This leaves a single glucose residue in a-(1,6) linkage to the 
main chain. The -1,6-glucosidase or -amylase activity of the debranching enzyme then 
catalyzes hydrolysis of the (1,6) linkage, leaving a polysaccharide chain with one branch 
fewer and  yielding free glucose. This is a minor fraction of free glucose released from 
glycogen (Fig 3), since that the major product of glycogen breakdown by phosphorylase  
activity is glucose-1-phosphate. Phosphoglucomutase catalyzes the reaction: glucose-1-
phosphate   glucose-6-phosphate. 
Glucose-6-phosphate is the first step of the glycolysis pathway if glycogen is the 
carbohydrate source of further energy needed. If energy is not immediately needed, the 
glucose-6-phosphate is converted to glucose, by the action of the enzyme glucose-6-
phosphatase (mainly in liver),  for distribution to various cells by blood, such as brain, 
erythrocytes, adipocytes, etc.  
The reactions involved in tissue glycogen synthesis and degradation are carefully controlled 
and regulated by hormones. The primary hormone responsible for conversion of glucose to 
glycogen is insulin. Opposite effects to glycogen metabolism have its antagonists: glucagon, 
adrenaline, cortisol, growth hormone which facilitate glycogenolysis in liver and muscles. 
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The principal enzymes of glycogen metabolism are glycogen synthase and glycogen 
phosphorylase, reciprocally regulated by allosteric effectors and covalent modification 
(through phosphorylation or dephosphorylation). Glycogen synthase is active when high 
blood glucose leads to intracellular glucose-6-P increase. Glycogen phosphorylase is active 
in the presence of high level of cyclic adenosine monophosphate (cAMP ) which suggests 
that the cells need chemical energy in the form of ATP.  
 
 
Fig. 3. Glycogenolysis 
Glucagon, synthesized by pancreatic -cells, and epinephrine (adrenaline), synthesized by 
adrenal medulla, regulate glycogen metabolism by covalent modification (phosphorylation 
and dephosphorylation) through cAMP cascades. Both hormones are produced in response 
to low blood glucose level. Glucagon activates cAMP formation in liver, while adrenaline 
activates its formation in muscle. Phosphorylation of the enzyme, via cAMP cascade, 
induced by adrenaline, results in further activation of glycogen phosphorylase. These 
regulatory processes ensure release of phosphorylated glucose from glycogen, for entry into 
glycolysis to provide ATP needed for muscle contraction. 
Insulin, produced in response to high blood glucose, antagonizes effects of the cAMP 
cascade induced by glucagon and adrenaline. It is the only hormone inducing cAMP 
decrease (Mayes, 1975; Voet & Voet, 2004b).   
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4.3 Glycolysis 
ATP depletion in cells, or low blood glucose level, lead to the activation of glycogenolysis 
and the enhancement of glucose degradation through glycolysis. Glycolysis is a central 
metabolic pathway of glucose metabolism, starting with glucose-6-phosphate,  produced by 
glycogenolysis or gluconeogenesis. Glucose-6-phosphate could also be synthesized directly 
from blood-derived glucose by the action of hexokinase in all human body cells or  by the 
action of glucokinase in hepatocytes.   
Glycolysis is the anaerobic catabolism of glucose. It occurs in cytosol of virtually all cells. 
The glycolytic pathway converts a molecule of glucose into 2 molecules of pyruvic acid and 
captures 2 molecules of ATP. If glycolysis proceeds in aerobic conditions 2 molecules of 
pyruvic acid enter mitochondria,  transforms into acetyl-CoA which is oxidized by the citric 
acid cycle. One cycle provides 12 mol ATP per one molecule of pyruvate. Aerobic conditions 
provide a mechanism for converting NADH back to NAD+ which is essential for glycolysis 
to operate (Fig 4). 
 
 
Fig. 4. Glycolysis and Gluconeogenesis 
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Under anaerobic conditions 2 molecules of pyruvate, under the action of lactate 
dehydrogenaze, and by using NADH2, convert to 2 molecules of lactate. The reaction is 
freely reversible (Haris, 1997; Mayes, 1975; Voet & Voet, 2004b;  users.rcn.com/.../I/ 
IntermediaryMetabolism.html).  
4.4 Gluconeogenesis 
If glucose is not obtained in the diet, during fasting , the body must produce new glucose 
from noncarbohydrate precursors by the proces of gluconeogenesis. The term  
gluconeogenesis means the generation (genesis) of new (neo) glucose. 
The production of glucose from other metabolites is necessary to maintain the glucose 
level in the blood as a fuel source by the brain, erythrocytes, kidney medulla and testes, 
since glucose is the sole energy source for these organs. During starvation, however, the 
brain can derive energy from ketone bodies which are converted to acetyl-CoA. The 
adipose tissue needs glucose which is also necessary for the synthesis of triacylglycerls 
and glycerophospholipids.  The main precursors for gluconeogenesis are lactate and 
alanine from muscle, glycerol from adipose tissue, and glucogenic amino acids from the 
proteolysis in peripheral tissues and proteins from the diet. The most of the amino acids, 
as well as their -keto acids, are TCA cycle intermediates. In addition, the 
gluconeogenetic processes are used to clear the intermediary products of metabolism of 
other tissues from the blood, e.g. lactate, produced by muscles and erythrocytes, and 
glycerol, which is continuously produced by adipose tissue.The principal organs 
responsible for gluconeogenesis are the liver and kidneys, which account for about 90% 
and 10% of the body’s gluconeogenic activity, respectively. Interestingly, the mammalian 
organs that consume the most glucose, namely, brain and muscle, carry out very little 
glucose synthesis (Gerich et al, 2001; King, 2011; Mayes,1975; Voet & Voet, 2004b; Woerle 
& Stumvoll, 2001).  
Gluconeogenesis is similar but not the exact reverse of glycolysis; some of the steps are the 
identical in reverse direction and three of them are new ones (Fig 4). In glycolysis energy 
barriers obstruct a simple reversal of glycolysis: reactions catalyzed by pyruvate kinase, 
phospho-fructokinase and hexokinase. These barriers are circumvented by new, special 
enzymes of gluconeogenesis: pyruvate carboxylase, phosphoenolpyruvate carboxykinase, 
fructoso-1,6-diphosphatase and glucose-6-phosphatase. The conversion of lactate to glucose 
begins with the oxidation of lactate, by the action of lactate dehydrogenase, to pyruvate. In 
the presence of ATP, pyruvate carboxylase and CO2 convert pyruvat to oxaloacetate. The 
enzyme, phosphoenolpyruvate carboxykinase (PEPCK) transfers oxaloacetate to 
phosphoenolpyruvate in the presence of GTP and by elimination of CO2. Thus, with the 
help of these two enzymes, and lactate dehydrogenase, lactate can be converted to 
oxaloacetate. The pyruvate and oxaloacetate are the intermediary products of catabolic 
pathway of many glycolytic amino acids. The next steps of reversal glycolysis continue just 
to formation of fructose-1,6-diphosphate, the substrate for fructose-1, 6-diphosphatase. 
Fructose-6-phosphate, formed by elimination of inorganic phosphate, converts to glucose-6-
phosphate (G6P). The energy required for the hepatic synthesis of glucose from lactate is 
derived from the oxidation of fatty acids. In the liver and kidney, G6P can be 
dephosphorylated to glucose by the enzyme glucose 6-phosphatase. This is the final step in 
the gluconeogenesis pathway.  
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4.4.1 Cory cycle  
Lactate, formed by the oxidation of glucose in skeletal muscles and by erythrocytes through 
the proceses of anaerobic glycolysis, is transported to the liver and kidney, where it re-forms 
glucose, which again become available via the circulation for oxidation in the tissues. This 
process is known as the Cory cycle or lactic acid cycle (Fig 5). 
4.4.2 Glucose-alanine cycle  
It has been noted that of the amino acids transported from muscles to the liver during 
starvation or under the action of cortisol, alanine predominate. Glucose-alanine cycle 
represents a cycling glucose from the liver to the muscles and alanine from muscles to liver, 
effecting a net transfer of amino nitrogen from muscle to liver and free energy from liver to 
muscle. At the level of muscles, pyruvate, formed by glycolysis,  transforms to alanine by 
the action of alanine transaminase (ALT) or glutamate pyruvat transaminase (GPT). The 
reaction is freely reversible; at the level of hepatocytes alanine transfers to pyruvate by the 
action of the same anzyme (Fig 5). 
Glycerol, necessary for the synthesis of triacylglicerols and glycerophosholipids is derived, 
initially, from the blood glucose since free glycerol cannot be utilised readily for the 
synthesis of these lipids  in tissues. Instead of free glycerol, adipose tissue uses -glycero 
phosphate or ”active glycerol" produced during degradation of glucose by glycolysis. 
 
 
 
 
 
 
 
 
 
Fig. 5. Cory cycle , glucose-alanine cycle  and  glycerol-glucose cycle 
www.intechopen.com
  
Type 1 Diabetes Complications 
 
118 
4.4.3 Glycerol - Glucose cycle  
Glycerol, a product of the continual lipolysis, diffuses out of the tissue into the blood. It is 
converted back to glucose by gluconeogenic mechanisms in the liver and kidney. Thus, a 
continous cycle exists in which glucose is transported  from the liver to adipose tissue  and, 
hence, glycerol is returned to be synthesized into glucose by the liver. Glycerokinase, which 
requires ATP, catalyzes the conversion of glycerol to -glycero phosphate. Glycerokinase is 
present in liver and kidney. The enzyme  -glycero phosphate dehydrogenase oxidizes -
glycero phosphate to the dihydroxacetone phosphate, the component of glycolysis, which 
enters the glycolytic pathway as a substrate for triose phosphate isomerase (Fig 4).  Thus, 
liver is able to convert glycerol to blood glucose by making use of above enzymes - some of 
the enzyme of glycolysis and specific enzymes of gluconeogenic pathway, fructose-1,6-
diphosphatase and glucose-6-phosphatase(Harris & Crabb, 1997; King, 2011; Mayes,1975).  
Glucose produced by gluconeogenesis in the liver and kidney is released into the blood and 
is subsequently absorbed by all human body cells especially brain, heart, muscle, and red 
blood cells to meet their metabolic needs. In turn, pyruvate,  lactate and glycerol produced 
in these tissues are returned to liver and kidney to be used as gluconeogenic substrates. 
5. The physiological regulation of carbohydrate metabolism  
5.1 Glucose homeostasis 
The maintaining of stable levels of blood glucose is one of the most finely regulated of all 
homeostatic mechanisms and one in which the liver, extrahepatic tissues and several 
hormones play a part. Even mild disruptions of glucose homeostasis can have adverse 
consequences. The physiological post absorptive serum glucose concentration in healthy 
humans range is 4. 4-5.8 mmol/L (80 to 110 mg/dL).  
Glycemia is controlled by several physiological processes. It tends to fluctuate to higher 
levels after meals, due to intestinal absorption of carbohydrates of low molecular weight 
present in the diet or broken down polysaccharides, such as starch or glycogen. On the 
other hand, glucose tends to decrease to lower levels induced by cell metabolism, 
particularly after stress, temperature regulation and physical exercise. Glucose can also be 
supplied via breakdown of cellular reserves of glycogen. Another input to glycemia levels 
is gluconeogenesis, whereby glycogen stored in the liver and skeletal muscles are 
depleted.  
The stability of the glycemia is a reflection of the balance between the rates of whole body glucose 
production and glucose utilization. The glucose homeostasis is tightly regulated by the levels of 
hormones and substrates in blood and by the physiologic functions of body tissues and 
organs (Carraway & Watts, 1986; Haris, 1997; King,2011).  
5.2 Hormonal regulation of glycemia  
The hormones involved in glycemia regulation include insulin (which lowers the blood 
sugar level) and other hormons which raise blood sugar, namely antagonists of insulin such 
as glucagon, epinephrine, cortisol,  growth hormone, thyreoid hormones (T3 and T4) and 
many others. The proper functions of these hormones is precise control of glucose 
concentration in the blood. Insulin and glucagon are two major hormones involved in 
regulation of blood glucose level. They are both secreted in response to blood sugar levels, 
but in opposite fashion. At the same time, enhanced insulin secretion induced increased 
glucagon secretion.  
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Insulin has a hypoglycemic effect. Secretion of insulin is a response to increased glucose 
level  in the blood. In addition to the direct effects of hyperglycemia in enhancing the uptake 
of glucose into both the liver and peripheral tissues, the hormon insulin plays a central role 
in the regulation of the blood glucose concentration. Similarly, as blood glucose falls, the 
amount of insulin secreted by the pancreatic islets goes down.   
Glucagon, as a direct antagonist of insulin, has a hyperglycemic effect. Secretion of glucagon  
is a response to decreased glucose level  in the blood (Chattoraj & Watts,1986;  Ginsberg, 
1990 a, 1990b; Mayes,1975; King, 2011).   
5.2.1 Insulin 
Insulin is a small protein consisting of an alpha chain of 21 amino acids linked by two 
disulfide (S—S) bridges to a beta chain of 30 amino acids. The precursor of insulin is a 
proinsulin, which contains C peptide (conective peptide). The conversion of proinsulin to 
insulin requires biologic proteolysis (Ginsberg,1990; Bowen, 2010; Harper, 1975; Chattoraj & 
Watts,1986). 
The stimulus for insulin secretion is a high blood glucose. Insulin is produced by ǃ cells of 
Langerhans islets in pancreas and is secreted into the blood as a direct response to 
hyperglycemuia. Beta cells have channels in their plasma membrane that serve as glucose 
detectors. When blood glucose levels rise (after a meal), insulin is secreted from the pancreas 
into the pancreatic vein, which empties into the portal vein system, so that insulin traverses 
the liver before it enters the systemic blood supply. Insulin acts to rapidly lower blood 
glucose concentration in several ways. It stimulates the active transport of glucose across 
plasma membranes through glucose transporter (GLUT 4) of muscle and adipose tissue. The 
liver, brain and red blood cells do not require insulin for glucose uptake.  Insulin is an 
anabolic hormone. It promotes anabolic processes in these cells, such as increasing the rate 
of glycogenesis, lipidogenesis and proteins synthesis. The cellular uptake of glucose from 
the blood have the net effect of lowering the high blood glucose levels into the normal 
range. Insulin stimulates cells in most tissues of the body to preferentially use glucose as 
their metabolic fuel. It increases cellular glucose utilization by inducing the synthesis of 
several important glycolytic enzymes, namely, hexokinase, glucokinase, 
phosphofructokinase, and pyruvate kinase. In addition, insulin inhibit gluconeogenesis in 
liver. All of these  physiological effects of insulin serve to lower blood glucose levels. In each 
case, insulin triggers these effects by binding to the insulin receptor - a transmembrane 
protein embedded in the plasma membrane of the responding cells. When the the glucose 
concentration in the blood falls, pancreas stops releasing insulin (Ginsberg, 1990 a, 1990b; 
Bowen, 2007; King, 2011). 
5.2.2 Amylin 
Pancreatic beta cells secrete  amylin, a peptide of 37 amino acids. All of its actions (inhibition 
of glucagon secretion, slowing down the stomach emptying, sending a satiety signal to the 
brain) tend to supplement those of insulin, reducing the level of glucose in the blood (King, 
2011; Silvestre et al, 2001; Young, 2005; users.rcn.com/.../I/IntermediaryMetabolism.html). 
5.2.3 Glucagon 
Glucagon is another 29 amino acid peptide hormone produced by pancreas. It is a 
hyperglycemic hormone (Bowen, 2007). Glucagon is produced by alpha (ǂ) cells of 
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Langerhans islets as proglucagon and proteolytically processed to yield glucagon within 
alpha cells of the pancreatic islets. Proglucagon is also expressed within the intestinal tract, 
where it is processed not into glucagon, but to a family of glucagon-like peptides (GLP) 
(Ginsberg,1990b; Bowen, 2007). Glucagon is secreted in response to hypoglycemia. It is 
active in liver and adipose tissue, but not in other tissues. This peptide hormone travels 
through the blood to specific receptors on hepatocytes and adipocytes. When the 
concentration of glucose in blood decreases,  ǂ cells of the pancreas begin to release 
glucagon. Glucagon stimulates hepatocytes to glycogenolysis and gluconeogenesis, 
resulting in hyperglycemia. It increases the amount of cAMP and stimulates lipolysis, 
contributing to reduction of the cellular glucose utilization, the increasing of lipolysis in 
adipose tissue, providing glycerol and free fatty acids which enter  oxidation cycle, 
producing the chemical energy (ATP) to most cells. Glycerol leaves the adipose tissue, and 
through the blood enters the hepatocytes where it may serve as the substrate in the process 
of gluconeogenesis (Fig 5). 
5.2.4 Epinephrine (adrenaline) 
Epinephrine is a hormone of adrenal medulla, which consists of masses of neurons that are 
the part of the sympathetic branch of the autonomic nervous system. Instead of releasing 
their neurotransmitters at a synapse, these neurons release them into the blood. Thus, 
although part of the nervous system, the adrenal medulla functions as an endocrine gland. It 
releases catecholamines: adrenaline (epinephrine) and noradrenalin (also called 
norepinephrine). 
Synthesis of both catecholamines begins with the amino acid tyrosine, which is taken up by 
chromaffin cells. Called the “fight or flight” hormone, adrenaline prepares the organism for 
mobilization of large amounts of energy and dealing with stress. Together with cortisol and 
growth hormone   they are named "stress hormones". Following release into blood, these 
hormones bind adrenergic receptors on target cells, where they induce essentially the same 
effects as direct sympathetic nervous stimulation. Adrenaline acts on liver and muscles. 
Mechanisms of the actions of adrenaline are the same as the mechanisms of glucagon. 
Through augmentation of cAMP in the cells, adrenaline initiates the enzyme cascade which 
leads to the activation of glycogen phosphorylase, leading to rapid breakdown of glycogen, 
inhibition of glycogen synthesis, stimulation of glycolysis and production of energy. In fat 
cell, it stimulates lipolysis, providing fatty acids as energy source in many tissues. 
Stimulation of lipolysis contributes to the reduction of the cellular glucose utilization and 
aids in conservation of dwindling reserves of blood glucose. The stimulation of hepatocytes 
to glycogenolysis and gluconeogenesis results in regulation of glycemia (Ginsberg,1990a; 
Chattoraj, & Watts, 1986; www.ncbi.nlm.nih.gov/books/NBK22429/).   
5.2.5 Glucocorticoids  
The glucocorticoids (cortisol as the principal one) get their name from their effect of raising 
the level of blood glucose. Glucocorticoids are a class of steroid hormones, synthesized and 
secreted from zone fasciculate of adrenal cortex,  that exert distinct effects on liver, skeletal 
muscles, and adipose tissue (Bjelakovic et al,2008,2009). The effects of cortisol are best 
described as catabolic, because it promotes protein breakdown and decreases protein 
synthesis in skeletal muscles. However, in the liver, it stimulates gluconeogenesis, inducing 
increased gene expression of several enzymes of the gluconeogenic pathway. Cortisol-
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induced gluconeogenesis results, primarily, in increased conversion of glycogenic amino 
acids (from protein breakdown in peripheral tissues) and glycerol (from fat) into glucose 
(Ginsberg, 1992c; Chattoraj & Watts, 1986; Gil, 1992; Litwak & Schmidt, 1997a; 
users.rcn.com/.../I/IntermediaryMetabolism.html.) 
5.2.6 Growth hormone (GH) 
Human growth hormone (GH; also called somatotropin), the protein of 191 amino acids,  
secreted by somatotrophs of the anterior part of pytuatary gland, regulates overall body and 
cell growth, carbohydrate, protein and lipid metabolism, and water-electrolyte balance.  The 
GH-secreting cells are stimulated by growth hormone releasing hormone (GHRH) from 
hypothalamus and inhibited by somatostatin. The release of GH might be regulated not only 
by hypothalamic GHRH, but also by ghrelin derived from the stomach (Kojima et al., 2005). 
GH promotes body growth by binding to receptors on the surface of liver cells and 
stimulates them to release insulin-like growth factor-1 (IGF-1, also known as somatomedin). 
GH exerts the hyperglycemic effect, stimulating glycogenolysis and lypolysis in peripheral 
tissues. In liver, GH also stimulates glycogenolysis and glyconeogenesis (Barry, 1992c; 
Frohman,1992; Litwak.& Schmidt, 1997b). 
5.2.7 Thyroid hormones 
Thyroid hormones are derivatives of the amino acid tyrosine bound covalently to iodine. 
The two principal thyroid hormones are: triiodothyronin (T3) and thyroxin (T4).  Thyroid 
hormones receptors are intracellular DNA-binding proteins that function as hormone-
responsive transcription factors. The effect of the hormone-receptor complex binding to 
DNA is to modulate gene expression, either by stimulating or inhibiting transcription of 
specific genes. It is likely that all cells in the body are targets for thyroid hormones. Thyroid 
hormones affect oxidative metabolism, especially the metabolism of carbohydrates. Thyroid 
hormones enhance glucose absorption and the utilization of carbohydrates. They stimulate 
both the synthesis and disposal of glucose Hypothyroidism or thyroid hormone deficiency 
leads to decrease in basal metabolic rate and hypoglycemia (Bowen, 2010;  Harper, 1975; 
Zmire et al, 1999). 
6. Physiological functions of liver, kidneys and brain  in carbohydrate 
metabolism 
Beside hormones, some organs have the important roles in glycemia regulation. Among 
them, the most important are liver, kidneys and brain.  
6.1 The role of liver in carbohydrate metabolism 
The metabolic activities of the liver are essential for providing fuel to the brain, muscle, and 
other peripheral organs. The liver removes two-thirds of the glucose from the blood and all 
of the remaining monosaccharides (Lehninger,1977; Cherrington,1999). The absorbed 
glucose is converted into glucose 6-phosphate by hexokinase and the liver-specific 
glucokinase, whose Km (Michaelis constant) for glucose is sufficiently higher than the 
normal circulating concentration of glucose (5mM). The liver plays a unique role in 
controlling carbohydrate metabolism by maintaining glucose concentrations in a normal 
range. It possesses the key enzymes for glucose intake (hexokinase and glucokinase) and for 
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releasing of glucose from hepatocytes (glucose-6-phosphatase). The liver has a great 
capability for synthesis and storing of glycogen (glycogenesis), and, in opposite direction, 
for glycogen breakdown (glycogenolysis).  Also, the liver is the place for gluconeogenesis. 
(King.2011, Nordlie et al, 1999; Radziuk & Pye, 2001). 
Glucose-6-phosphatase liberates free glucose molecules from hepatocytes into blood, 
catalyzing the following reaction: glucose-6-phosphate + H2O    glucose + Pi.The substrate 
for this enzyme is glucose-6-phosphate, the product of glycogenolysis or the end product of 
gluconeogenesis (Berg, 2002; Radziuk & Pye, 2001; Raddatz & Ramadori, 2007; Yamashita et 
al, 2001; Berg, 2002) .  
6.2 The role of kidney in carbohydrate metabolism 
Kidney may play a significant role in carbohydrate metabolism under both physiological 
and pathological conditions due to renal gluconeogenesis (King, 2011; Gerich et al., 2001). 
Although the liver is the major site of glucose homeostasis, the kidney plays a vital role in 
the overall process of regulating the level of blood glucose. Glucose is continually filtered by 
the glomeruli but is ordinarily returned completely to the blood by the enzymatic 
reabsorptive system of the renal tubules. The reabsorption of glucose is a process which is 
similar to that responsible for the absorption of this sugar from the intestine. The capacity of 
tubular system to reabsorb glucose is limited by the capacity of enzymatically systems of the 
tubule cells to a rate of about 350 mg/ minute, representing as tubular maximum for glucose 
(Tmg). Due to that capacity of the kidney, the definitive urine doesn’t contain glucose. When 
the blood levels of glucose are elevated, the glomerular filtrate may contain more glucose 
then can be reabsorbed; the excess passes into urine to produce glycosuria. In normal 
individuals, glucosuria occures when the venous blood  sugar excesss 9.5-10 mmol/L (170-
180 mg/100 ml). This level of the venous blood sugar is termed  the renal threshold for 
glucose (Mayes,1975; Woerle & Stumvoll, 2001). 
6.3 The role of brain in carbohydrate metabolism 
Glucose is the major energy source for maintenance of brain metabolism and function, 
except during prolonged starvation. However, the brain has limited glucose reserves and 
needs a continuous supply of glucose. Endogenous glucose provides more than 90% of 
energy needed for brain function (Cryer, 1997; Gerich et al, 2001; Halmos & Suba,2011; King, 
2011). Since the brain cannot synthesize glucose or store more than a few minutes’ supply as 
glycogen, it is critically dependent on a continuous supply of glucose from the circulation. 
Fatty acids do not serve as fuel for the brain, because they are bound to albumins in plasma 
and so do not traverse the blood-brain barrier. In prolonged starvation, ketone bodies, 
generated by the liver, partly replace glucose as fuel for the brain, (Cahill, 2006).  
Glucose is transported into brain cells by the glucose transporter GLUT3. This transporter 
has a low KM for glucose (1.6 mM). Thus, the brain is usually provided with a constant 
supply of glucose. At normal (or elevated) arterial glucose concentrations, the rate of blood-
to-brain glucose transport exceeds the rate of brain glucose metabolism. However, as arterial 
glucose levels fall below the physiological range, blood-to-brain glucose transport becomes 
limiting to brain glucose metabolism, and ultimately survival. 
Nowadays it is hypothesised that the brain, in particular the hypothalamus, has a great role 
in carbohydrate metabolism and glucose homeostasis. The brain is an insulin-sensitive 
organ. Brain-insulin action is required for intact glucose homeostasis. Receptors for insulin 
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are concentrated in hypothalamic area. Hypothalamus is the site of afferent and efferent 
stimuli between special nuclei and - cells and  cells of pancreas, and it regulates 
induction/inhibition of glucose output from the liver. Insulin gets across the blood-brain 
barrier, links to special hypothalamic receptors, regulating peripheral glucose (the 
hypothalamus-pancreas) (Halmos & Suba, 2011). In addition, the hypothalamus can affect 
metabolic functions by neuroendocrine connections: the hypothalamus-pancreas axis (the 
control of insulin and glucagone release), the hypothalamus-adrenal axis (the control of the 
release of  adrenaline and noradrenaline) and the hypothalamus-pituitary axis (release of 
glucocorticoids and thyroid hormones through adrenocorticotrophic hormone (ACTH) and 
thyroid-stimulating hormone (TSH) control, respectively, which modulate glucose 
metabolism. 
Recently, evidence is accumulating demonstrating that gastrointestinal hormones (peptides) 
are involved in regulating glucose metabolism through humoral gut–brain axis. Some of 
them are: ghrelin, neuropeptide Y (NPY), cholecystokinin - CCK, gastric inhibitory 
polypeptide - GIP,  glucagon-like peptide (GLP) etc. (Kojima & Kangawa, 2005; King, 2011; 
Korner &  Leibel, 2003; Neary et al, 2004 ; Young, 2005). 
7. Neuro-endocrine defence to hypoglycemia 
Generally, hypoglycemia is defined as a serum glucose level below (3.8 mmol/L or, 70 
mg/dL). Hypoglycemia is a rare disorder, considered as pathophysiological state rather 
than a disease. Just as pain and fever require identification of the underlying condition, 
hypoglycemia warrants diagnosis of the primary disorder causing the low plasma glucose 
concentration.  
The symptoms of hypoglycemia are not specific. For this reason it is necessary to 
demonstrate a low plasma glucose concentration concomitant with symptoms and 
subsequent relief of symptoms by correction of the hypoglycemia, i.e., Whipple's tirade. 
This triade can be considered to be the basis for a patient's symptoms, regardless of the 
cause of hypoglycemia (Service,1992). Whipple's triad considers: 1) symptoms consistent 
with hypoglycemia, 2) a low plasma glucose concentration, and 3) relief of symptoms 
after the plasma glucose level is raised. Hypoglycemia most often affects those at the 
extremes of age, such as infants and the elderly, but may happen at any age. Given the 
survival value of maintenance of the plasma glucose concentration, it is not surprising 
that very effective physiological mechanisms prevent or rapidly correct hypoglycemia 
have evolved.  
Hypoglycemic symptoms are related to the brain and the sympathetic nervous system. The 
central nervous system requires glucose as the preferred energy substrate. Though the brain 
accounts for only about 10% of body weight, it uses more than 30% of blood glucose. 
Hypoglycemic symptoms are mediated through both central and peripheral nervous 
systems. Once plasma glucose concentration fall belows 3.8 mmol/L or 70 mg/dL, a 
sequence of events begins to maintain glucose delivery to the brain and prevent 
hypoglycemia. 
The first of all events is the  stimulation of the autonomic nervous system and, after that, 
release of neuroendocrine hormones (counter-regulatory or anti-insulin hormones).  
Peripheral autonomic symptoms (adrenergic), including sweating, irritability, 
tremulousness, anxiety, tachycardia, and hunger, serve as an early warning system and 
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preceed the central neuroglycopenic symptoms due to cerebral glucose deprivation (e.g., 
confusion, paralysis, seizures, and coma) (Zammitt & Frier, 2005). 
A hierarchical hormonal response exists in response to decreasing blood glucose levels. As 
blood glucose drops, pancreatic ǃ-cell reduce insulin secretion. If blood glucose drops 
further, the pancreatic ǂ-cell  secrete glucagon and the adrenal medulla  release adrenaline. 
Both, glucagon and adrenaline, act rapidly to increase glucose availability and therefore are 
the two major counter-regulatory hormones. Cortisol and growth hormone are also 
released, but they are unable to prevent prolonged hypoglycemia withouth the preliminary 
actions of glucagone and adrenaline. In sensing hypoglycemia, the nutritionally deprived 
brain also stimulates the sympathetic nervous system, leading to neurogenic 
symptoms.Decreased levels of glucose lead to deficient cerebral glucose availability i.e., 
neuroglycopenia,  that can manifest as confusion, headache, difficulty with concentration. If 
the symptoms are overlooked, there can be irreversible brain damage. Eventually, the 
patient may go into coma and death. The adrenergic symptoms often precede the 
neuroglycopenic symptoms and, thus, provide an early warning system for the patient, 
(Cryer,1997; Heijboer et., 2006). 
8. Hypoglycemia as a result of inherited or acquired disorder of 
carbohydrates metabolism 
8.1 Hypoglicemia and inborn errors of carbohydrate metabolism 
Hypoglycemia is not a disease by itself, but its presence is an indication of a problematic 
health condition. As a relatively frequent common event in the pediatric newborn period 
(childhood), hypoglicemia may be a consequence of some inborn errors of carbohydrate 
metabolism (Service,1992; Sinclair,1979; Caraway & Watts, 1986). 
8.1.1 Defects in digestion & absorption of carbohydrates  
8.1.1.1 Inherited lactase deficiency (alactasia) 
Enzyme lactase is necessary to digest lactose to glucose and galactose in the small 
intestine. Lactase deficiency is a rare congenital disorder in which infants are born 
without lactase. If lactase is deficient,undigested lactose enters the large intestine, where it 
is fermented by colonic bacteria, producing lactic acid  and gases (hydrogen, methane, 
carbon dioxide).The gas produced creates the uncomfortable feeling of gut distention and 
the annoying problem of flatulence. The lactic acid produced by the microorganisms is 
osmotically active and draws water into the intestine, as does any undigested lactose, 
resulting in diarrhea. As children are weaned and milk becomes less prominent in their 
diets, lactase activity normally declines to about 5 to 10% of the level at birth (Gary,1978; 
Sinclair,1979; Tietz et al,1986). The simplest treatment is to avoid the consumption of 
products containing much lactose. Alternatively, the enzyme lactase can be ingested with 
milk products. 
8.1.1.2 Lactose intolerance 
Lactose intolerance is an inability to digest significant amounts of lactose due to an absence 
of the enzyme lactase in adult intestines. The symptoms of this disorder, which include 
diarrhea and general discomfort, can be relieved by eliminating milk from the diet (Maxton 
et al, 1990; Tietz et al,1986). 
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8.1.1.3 Sucrase deficiency 
Enzyme sucrase decomposes disaccharide sacharose to glucose and fructose molecules. 
There is a number of reports of an inherited deficiency of the disaccharidases, sucrase and 
isomalatase, occurring within the mucosa of the small intestine. Symptoms occur in early 
childhood following ingestion of sucrose. The symptoms are the same as those described in 
lactase deficiency except that they are evoked by the ingestion of table sugar (Gary,1978 ; 
Sinclair,1979; Tietz et al,1986 )  
8.1.1.4 Glucose galactose malabsorption 
Glucose Galactose Malabsorption (GGM)  is a genetic disorder caused by a defect in glucose 
and galactose transport across the intestinal brush border membrane. Normally, lactose in 
milk is broken down into glucose and galactose by lactase, an  ectoenzyme on the brush 
border, and the hexoses, having nearly identical chemical structure, are transported into the 
cell by the Na+-glucose cotransporter SGLT1 (Fig 6). The mutations causing the defect in 
sugar transport have been identified (Gary, 1978; Wright, 1998; Wright et al, 2002; Wright et 
al, 2004; Wright, 2003). 
 
 
Fig. 6. Sugar transport across intestinal apithelium (Wright  et al., 2004, modified) 
Glucose-galactose malabsorption is an autosomal recessive disorder in which affected 
individuals inherit two defective copies of the SGLT1 gene, located on chromosome 22. This 
disease presents in newborn infants as a life-threatening diarrhea. The diarrhea ceases 
within 1 h of removing oral intake of lactose, glucose and galactose, but promptly returns 
with the introduction of one or more of the offending sugars into the diet. We conclude that 
mutations in the SGLT1 gene are the cause of glucose-galactose malabsorption, and sugar 
transport is impaired mainly because the mutant proteins are either truncated or are not 
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targeted properly to the cell membrane. The glucose and galactose, if left untransported, 
draw water out of the body into the intestinal lumen, resulting in diarrhea.  
Although no cure exists for GGM, patients can control their symptoms (diarrhea) by 
removing lactose, sucrose and glucose from their diets. Infants showing a prenatal diagnosis 
of GGM will thrive on a fructose-based replacement formula and will later continue their 
"normal" physical development on a fructose-based solid diet. Older children and adults 
with severe GGM can also manage their symptoms on a fructose-based diet and may show 
improved glucose tolerance and even clinical remission as they age (Wright et al., 2001; 
Wright,1998; Gary, 1978). 
8.1.2 Galactosemia 
Galactose is found in the disaccharide lactose, the principal milk sugar, made from galactose 
and glucose. It will be recalled that galactose is required in the body, not only in the 
formation of milk lactose during lactogenesis in lactating mammary glands, but also as a 
constituent of the glucosphyngolipids (cerebrosides, globosides, gangliosides) and for the 
synthesis of mucopolysaccharides (MPS) or glucosaminoglycanes (GAG). 
Glucosaminoglycanes are linked to core proteins forming proteoglycanes. Proteoglycanes 
and glucosphyngolipids perform numerous vital functions within the body, some of which 
still remain to be studied (King, 2011; Segal, 1989). 
The disruption of galactose metabolism is referred to as galactosemia. Galactosemia can 
result from deficiencies of three different enzymes: galactose-1-phosphate uridyl transferase 
(GALT), galactokinase (GALK) and uridine diphosphate galactose 4-epimerase (GALE).   
8.1.2.1 Galactokinase deficiency  
Galactokinase is the first enzyme in the pathway of galactose metabolism, converting 
galactose to galactose-1-P. The only consequence of galactokinase deficiency is the 
development of cataract.  
8.1.2.2 Deficiency of galactose-1-phosphate uridyl transferase (GALT) 
The most common and severe form of galactosemia, called classic galactosemia or 
Galactosemia Type 1, is an inherited deficiency of GALT, the enzyme that converts 
galactose-1-phosphate (galactose-1-P) to uridine diphosphate galactose (UDPgalactose). 
Absence or deficiency of GALT prevents the conversion of galactose into glucose in liver. 
People with absent or deficient GALT have intolerance to galactose. 
When an infant or neonate is given milk the blood galactose level is markedly elevated 
(galactosemia), and galactose is found in urine (galactosuria). These can cause severe 
damage to eyes, kidneys, liver and brain. Afflicted infants fail to thrive. They vomit or have 
diarrhea after consuming milk and enlargement of liver and jaundice are common, 
sometimes progressing to cirrhosis. Cataracts will form, and lethargy and retarded mental 
development are also common. A cataract, the clouding of the normally clear lens of the eye, 
is a consequence of the accumulation of galactose in the lens of the eye; in the presence of 
high galactose amount and of aldose reductase, galactose is reduced to galactitol. The 
absence of the transferase in red blood cells is a definitive diagnostic criterion (Mayatepek et 
al, 2010).  
These problems can be prevented by removing galactose and lactose from the diet. In classic 
galactosemia conversion of UDP-galactose to UDP-glucose is blocked. The epimerase 
reaction is, however, present in adequate amounts, so that the galactosemic individual can 
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still form UDP-galactose from glucose. This explains the normal growth and development of 
affected children in spite of the galactose-free diets which are used to control the symptoms 
of the disease (Harper, 1975). 
In adults, the toxicity of dietary galactose appears to be less severe, due, in part, to the 
metabolism by alternative metabolic pathway of galactose-1-P by UDP-glucose 
pyrophosphorylase, which apparently can accept galactose-1-P in place of glucose-1-P. The 
levels of this enzyme may increase in the liver of galactosemic individuals, in order to 
accommodate the metabolism of galactose, later, after 10 years.  
8.1.2.3 Uridine diphosphate galactose 4-epimerase deficiency   
Uridine diphosphate galactose-4-epimerase (UDP-galactose-4-epimerase, GALE) converts 
UDP-galactose to UDP-glucose. Reaction is freely reversible (Fig 7). In this manner, glucose, as 
a unique  monosaccharide in systemic blood circulation in healthy subects , can be converted 
to galactose in many different tissues of human body if UDP-galactose-4-epimerase is present.  
Galactosemia due to epimerase deficiency is the rarest and most poorly understood form.  In 
most patients with GALE (or epimerase) deficiency, the defect presenting with clinical 
features is similar to classic galactosemia. The treatment for children with generalised GALE 
deficiency, as with GALT deficiency is the restriction of dietary galactose.  
Since galactose is an essential component of galactoproteins and galactolipids,  theoretically, 
in generalised GALE deficiency, no endogenous production of galactose is possible, with a 
resulting deficiency in galactolipids  and galacto-proteoglycanes production.  
The most common treatment is to remove galactose (and lactose) from the diet. The enigma 
of galactosemia is that, although elimination of galactose from the diet prevents liver disease 
and cataract development, the majority of patients still suffer from central nervous system 
malfunction,  most commonly a delayed acquisition of language skills. Females will also 
display ovarian failure (Sarkar et al, 2010; Segal, 1989; Walter et al, 1999). 
8.1.3 The inherited abnormalities in fructose metabolism 
Fructose is  monosacharide found in honey and in numerous vegetables and fruits.  
Disacharide sucrose consists of one molecule fructose attached to a molecule of glucose. It 
should be mentioned that fructose constitutes the main sugar of seminal fluid. Three 
inherited abnormalities in fructose metabolism have been identified: essential fructosuria, 
hereditary fructose intolerance and hereditary fructose-1,6-bisphosphatase deficiency 
(Baerlocher  et al,1978; Gitzelmann et al., 1989; Froesch, 1978). 
After absorption by the proces of facilitated diffusion,  fructose enters hepatocytes , by  the 
portal blood. A specific kinase, fructokinase, in liver and kidney catalyzes the 
phosphorylation of fructose to fructose 1-phosphate. Fructose 1-phosphate is cleaved to D-
glyceraldehyde and dihydroxyacetone phosphate by aldolase B, an enzyme found in the 
liver. D-glyceraldehyde enters glycolysis via phosphorylation to glyceraldehyde 3-
phosphate catalyzed by triokinase. The two triose phosphates, dihydroxyacetone phosphate 
and glyceraldehyde 3-phosphate, may either be degraded by glycolysis or may be substrates 
for aldolase A , the enzyme which forms fructose1,6-diphosphate and hence 
gluconeogenesis, which is the fate of much of the fructose metabolized in the liver. 
Fructose  ATP ructose 1 P  ADP
Fructose 1 P  dihydroxyacetone P  glyceraldehyde
fructokinase F
aldolaseB
    
      
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8.1.3.1 Essential fructosuria 
Essential fructosuria is a benign metabolic disorder caused by the lack of fructokinase, 
which is normally present in liver and kidney cortex. The disorder is asymptomatic and it 
may go undiagnosed.  
8.1.3.2 Hereditary fructose intolerance (aldolase B deficiency)  
Hereditary fructose intolerance is a potentially lethal disorder resulting from a lack of 
aldolase B which decomposes fructose-1-phosphate to dihydroxyaceton-phosphate plus 
glycerine aldehyde. The disorder is characterized by severe hypoglycemia and vomiting 
following fructose or sacharose  intake. Prolonged intake of fructose by infants with this 
defect leads to vomiting, poor feeding, jaundice, hepatomegaly, hemorrhage and eventually 
death. The hypoglycemia that results, following fructose uptake, is caused by fructose-1-
phosphate inhibition of glycogenolysis, by interfering with the phosphorylase reaction and 
inhibition of gluconeogenesis at the deficient aldolase step. Patients remain symptom free 
on a diet devoid of fructose and sucrose(Baerlocher et al, 1978; Gitzelman at al, 1989; 
Odièvre et al, 1978). 
8.1.3.3 Hereditary fructose-1,6-bisphosphatase deficiency 
This disordered is characterized by hypoglycemia, ketosis and lactic acidosis and oftern 
lethal course in newborn infants. Due to enzyme defect gluconeogenesis is severely 
impaired. Gluconeogenis precursors, such as amino acids, lactate and ketones, accumulate 
as soon as liver glycogen stores are depleted (Asberg et al, 2010; Baerlocher et al, 2010;  
Froesch, 1978; Mortensen, 2006;  Song, 2010; Zaidi, 2009).  
8.1.4 The glycogen storage diseases (GSDs) 
Glycogen is the storage form of glucose and is present in virtually all living cells, although 
the liver is primary organ for storage and subsequent release of glucose into the circulation. 
Glycogen biosynthesis from glucose (glycogenesis), along with the release of glucose from 
glycogen by the process of glycogenolysis, is highly regulated process  that aids in the 
maintaing of normal blood glucose concentration during fasting.  
During the last century, patients who have deficient activity in virtually every enzyme 
important in the normal synthesis, degradation or regulation of glycogen have been 
identified. Most of them are inherited in an autosomal recessive manner. Several inborn 
errors of glycogen metabolism have been described, and they result from mutations in genes 
that code for proteins involved in various steps of glycogen synthesis, degradation, or 
regulation. Glycogen storage diseases are characterized by an abnormal tissue concentration 
(>70 mg per gram of liver or 15 mg per gram of muscle tissue of normal or abnormal 
structure of glycogen). Hypoglycemia is the main biochemical consequence of GSD type I 
and some of the other GSDs. The basis of dietary therapy is nutritional manipulation to 
prevent hypoglycemia and improve metabolic dysfunction (Heller et al, 2008; Mayatepek et 
al, 2010). 
All glycogenosis may divide in two groups: hepatic and muscular forms of glycogenosis. 
The various hepatic enzyme deficiencies are expressed primarily as hypoglycemia and 
hepatomegaly. In glycogenosis type I, III and VI there is limitation in the output of glucose 
from hepatic tissue, and hypoglycemia is an prominent laboratory sing. (Goldberg & 
Slonim, 1993; Heller et al, 2008; Howell, 1978; Wolfsdorf.& Weinstein, 2003). 
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8.1.4.1 Glycogen storage disease type I 
Glycogen storage disease type I (glucose-6-phosphatase deficiency; von Gierke disease; 
Hepato-renal glycogenoses). GSD type I (or von Gierke disease) is an autosomal recessive 
disorder that is caused by deficient G6Pase activity. Glucose-6-phosphatase (G6Pase), an 
enzyme found mainly in the liver and kidneys, plays a critical role in blood glucose 
homoeostasis,  providing glucose during starvation. One of the important functions of the 
liver and, to a lesser extent, of the kidney cortex is to provide glucose during conditions of 
starvation. Glucose is formed from gluconeogenic precursors in both tissues, and in the liver 
also from glycogen. Both glycogenolysis and gluconeogenesis result in the formation of 
glucose 6-phosphate, which has to be hydrolysed by G6Pase before being liberated as 
glucose into the circulation. 
Glucose-6-phosphatase is the enzyme that catalyzes the last step of glycogenolysis and 
gluconeogenesis in liver and kidneys, i.e. the hydrolysis of glucose 6-phosphate to free 
glucose and inorganic phosphate. Its genetic deficiency is characterized by the association of 
hepatomegaly and nephromegaly due to the accumulation of large amounts of glycogen in 
these organs, with hypoglycaemia and lactic acidosis.  
GSD type Ia  is the most frequent form of glycogenosis, accounting for about 80% of the 
cases. It is caused by a lack of G6Pase activity, which is easily demonstrated by measuring 
the activity of this enzyme in a liver biopsy specimen. The deficiency of G6Pase activity is 
caused by mutations in the gene encoding this enzyme.  
 
 
Fig. 7. The glucose-6-phosphatase system 
On the basis of the imunological studies, by using the antibodies against to several of five 
components of glucose-6-phosphatase, GSD type I has been subcategorised  into types a, b, 
and c, with type a as the most common, but all types have similar clinical manifestation as 
hypoglycemia and hepatomegaly  due to the deposition of glycogen with normal structure. 
Fasting-induced hypoglycemia may be extreme, and with combination with lactic acidosis. 
Although severely affected patients may suffer brain damage in early infancy, this is not 
usually the case, and the most patients have normal intelligence. During starvation, 
however, the brain can derive energy from ketone bodies  which are converted to acetyl-
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CoA. It is likely that the nervous system is able to metabolise such substance as ketones and 
lactic acid. 
Glucose-6-phosphatase  consists of a hydrolase, whose catalytic site faces the lumen of the 
organelle and of translocases required for the transport of glucose 6-phosphate, Pi and 
glucose (Figure 7). Glucose 6-phosphate is transported into the lumen of the endoplasmic 
reticulum by a specific transporter before being hydrolysed by glucose-6-phosphatase, a 
transmembrane protein with its catalytic site oriented towards the lumen of the 
endoplasmic reticulum. Glycogen storage disease type Ia (GSD Ia) is due to a defect in 
glucose-6-phosphatase catalytic site and glycogen storage disease type Ib, to a defect in the 
glucose 6-phosphate transporter (Schaftingen  and Gerin, 2002). 
8.1.4.2 Debranching enzyme deficiency (type III glycogen storage disease; limit 
dextrinosis;  Cori’s disease) 
Type III glycogen storage disease (amylo-1, 6-glucosidase (debrancher) deficiency) most 
often affects only liver, but may affect muscles as well. In this form of glycogen storage 
disease, a glycogen accumulates which has a structure resembling the limit dextrin 
produced by degradation of of glycogen by phosphorylase a , which is free of debrancher 
(amylo-1, 6-glucosidase) activity. Early in life, hepatomegaly and growth retardation may be 
striking. In contrast to patients with Type I glycogenosis, moderate enlargement of the 
spleen is sometime seen. Glycogen of abnormal structure frequently accumulates in muscle 
and heart, as well as in the liver. In the older patients it may cause a chronic progressive 
myopathy and cardiomegaly. With muscle involvement, the serum creatine phosphokinase 
(CPK) activity is elevated, and patients are usually classified as having type III b diseases. 
There is no renal enlargement in this disease. Generally, the clinical course of this disease is 
milder than that of Type I glycogenoses.  
8.1.4.3 Type VI glycogenosis (hepatic phosphorylase deficiency; Hers’ disease) 
Large group of patients with hepatic forms of the glycogen storage diseases have increased 
hepatic glycogen (with normal structure ) and a reduction to about 25 percent normal of 
hepatic phosphorylase activity. Patients with increased liver glycogen and profound 
reduction in liver phosphorylase activity (and normal activating system) continued to be 
observed. Hypoglycemia is present (Wolfsdorf & Weinstein, 2003; Heller et al, 2008). 
8.1.4.4 Glycogen synthase deficiency (type 0 glycogen storage disease; GSD0) 
Type 0 glycogen storage disease (GSD0) is caused by deficiency of the hepatic isoform of 
glycogen synthase (Weinstein et al, 2006). Although GSD0 has been classified as a glycogen 
storage disease, this is a misnomer. In contrast to all other types of glycogenoses, which are 
characterized by increased glycogen storage, deficiency of glycogen synthase causes a 
marked decrease in liver glycogen content. GSD0 is the only GSD not associated with 
hepatomegaly and hypoglycemia typically is milder than in the other types of GSD 
(Wolfsdorf & Weinstein, 2003; Weinstein, 2006).  
Patients with GSD0 have fasting ketotic hypoglycemia. Most children are cognitively and 
developmentally normal. Until recently, the definitive diagnosis of GSD0 depended on the 
demonstration of decreased hepatic glycogen on a liver biopsy. The need for an invasive 
procedure may be one reason that this condition has been infrequently diagnosed. Mutation 
analysis of the GYS2 gene (12p12.2) is a non-invasive method for making this diagnosis in 
patients suspected to have this disorder. 
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8.1.5 Disorders of gluconeogenesis 
A key role of gluconeogenesis is in the maintenance of blood sugar. Deficiency of any 
enzyme participating in gluconeogenesis can lead to hypoglycemia with  lactic acidosis. 
Inborn deficiencies are known of each of the four enzymes of the glycolytic-gluconeogenic 
pathway that ensure a unidirectional flux from pyruvate to glucose: pyruvate carboxylase, 
phosphoenolpyruvate carboxykinase, fructose-1,6-bisphosphatase, and glucose-6-
phosphatase (van den Berghe, 1996). 
8.1.5.1 Pyruvate carboxylase deficiency (PCD)  
Pyruvate carboxylase, a member of the biotin-dependent enzyme family, catalyses the ATP-
dependent carboxylation of pyruvate to oxaloacetate. Pyruvate carboxylase is an important 
enzyme in gluconeogenesis. Deficiency of pyruvate carboxylase can lead to hypoglycemia 
with lactic acidosis. Pyruvate carboxylase deficiency is a rare disorder that can cause 
developmental delay and failure to thrive starting in the neonatal or early infantile period. 
PCD results in malfunction of the citric acid cycle and gluconeogenesis, thereby depriving 
the body of energy. Based on the severity of the clinical presentation and the biochemical 
disturbances, two clinical forms have been described. The milder form A presents in infancy 
with delayed neurological development, chronic lactic acidemia and a normal lactate to 
pyruvate ratio. Longer survival, but with severe clinical sequelae, is common in the mild 
form A. The complex form B presents neonatally or in early infancy with severe metabolic 
acidosis, lactic acidosis, ketosis, and hepatomegaly (Jitrapakdee &. Wallace, 1999;  Ahmad  
et al., 1999). 
8.1.5.2 Phosphoenolpyruvate carboxykinase deficiency  
Phosphoenolpyruvate carboxykinase is an important enzyme in gluconeogenesis. It is found 
in both cytosol and mitochondria of the liver cells. Deficiency of the enzyme, a rare inherited 
disorder, can cause severe, persistent neonatal hypoglycaemia and liver impairment 
(Hommes et al, 1976; Vidnes & Sovik, 1976). 
8.1.5.3 Fructose-1,6-diphosphatase (FDPase) deficiency  
Fructose-1,6-diphosphatase (F1,6DPase) catalyzes the conversion of fructose-1,6-
diphosphate (F1,6DP) to fructose-6-phosphate. The F1,6BPase reaction is a major point of 
control of gluconeogenesis. Fructose-1,6-diphosphatase (FDPase) deficiency is an autosomal 
recessive disorder caused by a mutation of the FDP1 gene and results in impaired 
gluconeogenesis ( Froesch, 1978; Gitzelmann et al, 1989; Hellerud, 2010).  
Patients with FDPase deficiency typically present in the newborn period with symptoms or 
signs related to hypoglycemia and metabolic acidosis following ingestion of fructose. 
Patients lacking FDPase accumulate intrahepatocellular fructose-1,6-bisphosphate (FDP) 
which inhibits gluconeogenesis and, if intracellular phosphate stores are depleted, inhibits 
glycogenolysis. The inability to convert lactic acid or glycerol into glucose leads to 
hypoglycemia and  lactic acidosis (Asberg et al, 2010; Hellerud, 2010; Song, 2011; Zaidi, 
2009; Mortensen, 2006). The accumulation of fructose 1,6-diphosphate (FDP) inhibits 
phosphorylase a in liver, the first  enzyme of glycogenoslysis. 
8.1.5.4 Glycero kinase deficiency  
Glycerol kinase (GK) catalyzes the phosphorylation of glycerol to glycerol 3-phosphate 
(G3P) which is important in the formation of triacylglycerol (TAG) and fat storage. GK is at 
the interface of fat and carbohydrate metabolism. GK deficiency (GKD) is an X-linked 
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inborn error of metabolism that is characterized biochemically by hyperglycerolemia and 
glyceroluria and is due to mutations within or deletions of the GK gene on Xp21 (Rahib et al, 
2007). Isolated GKD can occur in patients with or without symptoms, mainly due to 
disturbed energy homeostasis associated with hyperketotic hypoglycemia (Sjarif et al, 2004). 
The greater importance of glycerol as a gluconeogenetic substrate in children than in adults 
may explain the episodes in young patients with GKD, often elicited by catabolic stress 
(Hellerud et al, 2004).  
8.1.6 Leucine-sensitive hypoglycemia  
This type of hypoglycemia was reported in 1956 by Cochrane who described children who 
became hypoglycemic on a casein-rich diet and whose symptoms worsened on feeding on 
high protein and low carbohydrate diet. The one-third of all infants with unexplained 
hypoglycemia may be sensitive to leucin. Presentation is most often in the first year of life.A 
common symptom is the development of convulsion after milk-feeding, (MacMullen et al., 
2001) .  
Leucine produces hypoglycemia by causing the release of insulin from the pancreas islet 
cells. The hypoglycemia found in maple syrup urine diseases is probably caused by high 
circulating levels of leucin. Two-thirds of the infants who have had leucine-sensitive 
hypoglycemia have subsequently mental retardation and neurological disorders (Roe &, 
Kogut, 1982; Sinclair, 1979). 
8.1.7 Hyperinsulinism/hyperammonemia (HI/HA) syndrome 
Hyperinsulinism is the most common cause of hypoglycemia in early infancy. Congenital 
hyperinsulinism, is usually caused by genetic defects in beta-cell regulation, including a 
syndrome of hyperinsulinism plus hyperammonemia (Kelly et al., 2001; Kogut, 1982; 
Stanley, 1997). 
The hyperinsulinism/hyperammonemia (HI/HA) syndrome is a form of congenital 
hyperinsulinism in which affected children have recurrent symptomatic hypoglycemia 
together with asymptomatic, persistent elevations of plasma ammonium levels. The 
disorder is caused by dominant mutations of the mitochondrial enzyme, glutamate 
dehydrogenase (GDH), that impair sensitivity to the allosteric inhibitor, GTP. These 
data confirm the importance of allosteric regulation of GDH, as a control site for amino 
acid-stimulated insulin secretion and indicate that the GTP-binding site is essential for 
the regulation of GDH activity by both GTP and ATP (MacMullen et al, 2001; 
Kogut,1982).  
9. Hypoglycemia as results of acquired disorders of carbohydrates 
metabolism  
9.1 Liver and kidney disorders 
Although hypoglycemia is usually linked with diabetes, there are various types of 
conditions, which are generally rare, that can cause it even in those who do not have 
diabetes. Any disorder or abnormality in the functioning of the liver can disturb the process 
of blood-sugar regulation, resulting in hypoglycemia. On the other hand, disorders in  
kidney can cause problems in excretion of certain medications. Hence, kidney disorders can 
be one of the major causes of low blood sugar. 
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9.1.1 Hypoglycemia in liver disorders 
Symptomatic hypoglycemia is uncommon in liver diseases because glucose homeostasis  can be 
maintained with as little as 20 per cent of healthy parenchymal cells, but biochemical 
hypoglycemia has been reported in a wide variety of aquired hepatic diseases. The 
hypoglycemia of Reye’s syndrome and sepsis, as well as alcohol hypoglycemia, are considered 
to be the consequence of hepatic disturbance. Acute viral hepatitis results in serious impairment 
in hepatic glycogen synthesis and gluconeogenesis and frequently gives rise to fasting 
hypoglycemia (Felig et al., 1970). Glycogen stores rapidly disappear as liver disease (including 
cirrhosis due to alcoholism) progresses, causing recurrent hypoglycemia (Service, 1992).  
Reye syndrome is a fatal disease, most commonly occuring following some virus infections 
(influenza A, influenza B, herpes, varicella zoster and several other common viral 
infections). Epidemiologic evidence suggests that aspirin plays a potentiating role in the 
pathogenesis of this syndrome. The hepatic dysfunction appears to be the primary error and 
the direct result of a mitochondrial disturbance that causes secondary metabolic 
derangement, (hyperamoniemia, hypoprotrombinemia without hyperbilirubinemia), 
including  hypoglycemia.   
Hypoglycaemia in patients with hepatocellular carcinoma usually occurs during the 
terminal stage of the illness, but there are patients with hepatocellular carcinoma who 
develop hypoglycaemia early in the course of their illness. Hypoglycemia occurs 
predominantly as a paraneoplastic manifestation of hepatocellular carcinoma, (Sorlini et al., 
2010; Thipaporn et al., 2005; Young, 2007).  
Ethanol is a potent hypoglycemic agent, causing decreased endogenous glucose production 
and glycogenolysis. The volume of alcohol intake is correlated with the degree of resulting 
hypoglycemia (Raghavan et al., 2007; Smeeks, 2008). Ethanol-induced hypoglycemia arises 
from inhibition of gluconeogenesis as a result of the increase in the NADH-NAD ratio, which 
suppresses the conversion of lactate to pyruvate, glycerophosphate to dihydroxyacetone 
phosphate, and glutamate to -ketoglutarate  and several tricarboxylic cycle reactions. Ethanol 
reduces rates of hepatic glucose production, supresses plasma insulin concentration, increases 
plasma lactate concentration, beta hydroxybutirate, glycerol and free fatty acids, and increases 
lactate-pyruvate and beta-hydroxybutirate-acetoacetate ratios. Hypoglycemia usually 
develops within 6 to 36 hours of the ingestion, of even moderate amounts of ethanol by 
persons chronically malnouriched or by healthy persons who have missed one of the meals. 
Healthy children  are especially susceptible to ethanol hypoglycemia. Blood ethanol levels may 
not be elevated when the patient is hypoglycemic. Healthy children are especially  susceptible 
to ethanol hypoglycemia. Blood ethanol levels may not be elevated when the patient is 
hypoglycemic( Arky, 1989;  Badawy, 1977; Service, 1992). 
9.1.2 Hypoglycemia in kidney disorders 
Kidneys  play a significant role in carbohydrate metabolism under both physiological and 
pathological conditions due to renal gluconeogenesis. Hypoglycemia in patients with renal 
failure may be due to inadequate gluconeogenic substrate availability. It seems that 
disturbances in renal gluconeogenesis together with lower degradation of insulin played the 
key role in creating hypoglycaemia in patients with renal diseases. Hypoglycemia should be 
suspected in any patient with renal failure who exhibits any change in mental or neurologic 
status (Arem, 1989; Rutsky,1978). Also, kidney disease is a frequent cause of adverse 
medication reactions due to  the problems in excretion of certain medications and, therefore, 
causing hypoglycemia in older adults (Gerich, 2001).  
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9.2 Hormonal disturbances and hypoglycemia 
Adrenocortical insufficiency or Adrenocortical hypofunction is defined as the deficient 
production of glucocorticoids or mineralocorticoids, or both. Hypoglycemia is common in 
adrenocortical insufficiency. Primary adrenocortical insufficiency (Addison’s disease) is due 
to destruction of the adrenal cortex, whereas in secondary adrenocortical insufficiency 
impaired cortisol production is due to deficient ACTH production. Spontaneous 
hypoglycemia has been reported to be a frequent finding in isolated ACTH deficiency. The 
cause for primary adrenocortical insufficiency is autoimmune destruction or tuberculosis of 
the adrenal cortex.  
Hypoglycemia in hypopituitarism is common in children under 6 years of age but less so 
beyond that age. Asymptomatic hypoglycemia has been observed in isolated growth 
hormone deficiency after prolonged fasting (Tyrrell, 1992). 
Insulinoma. Insulin-producing tumors of pancreas can cause severe hypoglycemia; among 
these are islet cell adenoma and carcinoma (insulinoma). Insulinoma is uncommon  in 
persons less than  20 years of age and is rare in those less than 5 years of age. Of the patients  
with insulinoma, approxymately 87 per cent have single benign tumors. These tumors are 
most common in women (60%), with median age of diagnosis 50 years (Service, 1992). 
9.3 Reactive hypoglycemia 
The post-prandial hypoglycemia occurs immediately following meals, with no known 
causes (idiopathic reactive hypoglycemia, RH) (Krinsley & Grover, 2007).  
Alimentary hypoglycemia, another form of RH related to prior upper GI surgery (Guettier, 
2006), results from rapid glucose absorption into the intestine and increased insulin 
secretion after every meal. The food stimulated hypoglycemia usually cause symptomes 
mediated by the autonomic nervous system - sweating, shakiness, anxiety, palpitations, and 
weakness, and rarely those of impairment of central nervous system function. The food 
deprived hypoglycemia, on the other hand, usually result in impariment of central nervous 
system functions - reduced intellectual capacity, confusion, irritability, abnormal behavior, 
convulsions and coma (Service,1992). 
Infections. Hypoglycemia often occurs during or following acute infections in older adults. 
Infection-related hypoglycemia increases the risk of death and morbidity among persons over 
age 70 Secretion of glucagon, epinephrine, and growth hormone during hypoglycemia 
diminishes significantly after age 65, reducing autonomic warning symptoms in older adults. 
Sepsis as a cause of hypoglycemia should be readily apparent. The mechanism for 
hypoglycemia with sepsis is not well defined. Depleted glycogen stores, impaired 
gluconeogenesis, and increased peripheral utilization of glucose may all be contributing factors. 
Laboratory testing can confirm the suspicion of hepatic dysfunction (Rattarasarn, 1997). 
9.3.1 Hypoglycemia due to drug medications  
Insulin treatment of Diabetes mellitus. Hypoglycaemia is a serious, frequent and recurrent 
complication of treatment of diabetes mellitus with insulin, which may become a direct 
danger to the patient's life. Hypoglycaemia represents the limiting factor to obtain good 
glycemic control. Dysregulation of counteracting mechanisms and autonomic nervous 
system neuropathy contribute to a strong increase in the incidence of hypoglycaemia in type 
1 diabetic patients, but also in long lasting type 2 diabetic patients (Cryer, 2001, 2008). 
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Predictors of hypoglycemia in patients with type 2 diabetes include treatment with insulin 
and duration of insulin treatment, a history of previous hypoglycemia. Primary risk factors 
for hypoglycemia in decreasing importance have been reported as age over 64, current 
insulin treatment, sulfonylurea treatment, polypharmacy, renal impairment and previous 
hypoglycemic episodes (Miller et al., 2001). 
Antibiotics. Pentamidine used in treating opportunistic infections associated with 
immunosuppression (e.g. Pneumocystis pneumonia) and protozoan parasites, causes severe 
hypoglycemia by increasing insulin secretion. Isoniazid causes hypoglycemia through 
cytotoxic hepatic damage (Service, 1992). 
Sulfonamides and Fluorquinolones have been known to cause significant, life-threatening 
hypoglycemia by increasing insulin secretion. 
Cardiac medications. Beta-blockers inhibit glycogenolysis and are most likely to be 
associated with hypoglycemia in older adults. Isolated reports indicate that angiotensin-
converting enzyme inhibitors can cause hypoglycemia by increasing insulin sensitivity.  
Salicylates. It has been determined more recently that salicylates, such as aspirin, decrease 
serum glucose by reversing or inhibiting the process of insulin resistance related to 
generalized inflammatory responses. 
Psychotropic medications. It should be avoided haloperidol in older adults with a history of 
hypoglycemia, or sulfonylurea or insulin use, due to the risk of severe hypoglycemic 
interactions. Tricyclic antidepressants, chlorpromazine, MAO inhibitors, and lithium also 
have been reported to cause severe hypoglycemia. 
Quinolines. Quinines, used as an anti-malarial and anti-arrhythmic agents, have strong 
hypoglycemic properties, increasing insulin secretion as the sulfonylureas do (Service, 1992). 
10. Conclusion 
Hypoglycemia is defined as a serum glucose level below (3.8 mmol/L or, 70 mg/dL). The 
plasma glucose level is tightly controlled throughout life in the normal individual. The 
stability of the plasma glucose level is a reflection of the balance between the rates of whole 
body glucose production and glucose utilization. The physiological post absorptive serum 
glucose concentration in healthy humans range is 4.4-5.8 mmol/L (80 to 110 mg/dL). 
Variation in blood glucose levels above or below the normal range usually indicate to 
serious diseases. Even mild disruptions of glucose homeostasis can have adverse 
consequences. 
Hypoglycemia most often affects those at the extremes of age, such as infants and the 
elderly, but may happen at any age, in neonatal period and early childhood As a relatively 
frequent common event in the pediatric newborn period (childhood), hypoglicemia may be 
a consequence of some inborn errors of carbohydrate metabolism. In adults, hypoglycemia 
is a result of acquired disorders, primarily due to disturbance of physiological function of 
some organs (liver, kidney, CNS) or manifests disorders of some endocrine glands,  
involved in carbohydrate metabolism .  
The symptoms of hypoglycemia are not specific and are related to disturbance of the brain 
and the sympathetic nervous system. The  stimulation of the autonomic nervous system 
produces sweating, pale skin, irritability, anxiety, weakness, hunger, nausea,  serving as an 
early warning system and preceding the neuroglycopenic symptoms due to cerebral glucose 
deprivation, e.g. headache, confusion, inability to concentrate or pay attention, mental 
confusion, difficulty in thinking, changes in vision, lethargy, sleepiness, stupor. 
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Biochemical hypoglycemia has been reported in a wide variety of acquired hepatic and 
renal diseases. Also, kidney disease is a frequent cause of adverse medication reactions due 
to the problems in excretion of certain medications and, therefore, causing hypoglycemia in 
older adults due to drug medications. Hypoglycaemia is a serious, frequent and recurrent 
complication of diabetes mellitus treatment with insulin, which may  become a direct 
danger to the patient's life.  
Laboratory diagnosis of hypoglycemia is very important in medical praxis, especially in 
pediatric praxis, suggesting some inborn errors of carbohydrate metabolism, or, in adults, 
suggesting hepatic disorders, renal failure, and cardiac disorders, neuropsychiatric 
disorders, etc.  
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